Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2013-01-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/annrheumdis-2012-202641PMID 23355079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study

  2013cited by this paper
• The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study

  2013cited by this paper
• A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

  2012cited by this paper
• Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.

  2012cited by this paper
• A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

  2011cited by this paper
• Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?

  2011cited by this paper
• A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

  2010cited by this paper
• Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

  2008cited by this paper
• Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

  2007cited by this paper
• Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

  2007cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

  2006cited by this paper
• Psoriatic arthritis imaging: a review of scoring methods

  2005cited by this paper
• How to predict prognosis in early rheumatoid arthritis.

  2005cited by this paper
• Psoriatic arthritis: epidemiology, clinical features, course, and outcome

  2005cited by this paper
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004cited by this paper
• TNFalpha therapy in psoriatic arthritis and psoriasis.

  2004cited by this paper
• Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change

  2004cited by this paper
• TNFα therapy in psoriatic arthritis and psoriasis

  2004cited by this paper
• A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

  2003cited by this paper
• A method to score radiographic change in psoriatic arthritis

  2001cited by this paper
• How to read radiographs according to the Sharp/van der Heijde method.

  2000cited by this paper
• T cell derived cytokines in psoriatic arthritis synovial fluids

  1998cited by this paper
• Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

  1998cited by this paper
• Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Open Access Research Article Risk Factors for Radiographic Progression in Psoriatic Arthritis: Subanalysis of the Randomized Controlled Trial Adept

  year unknowncited by this paper

• Effectiveness of Biologics on Preventing the Development of Psoriatic Arthritis in Psoriasis Patients: A Systematic Review

  2026cites this paper
• Tuft resorption in patients with psoriatic arthritis.

  2025cites this paper
• The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis

  2025cites this paper
• Increased Musculoskeletal Surgery Rates During Diagnostic Delay in Psoriatic Arthritis: A Retrospective Cohort Study

  2025cites this paper
• Recommandations Tunisiennes de Bonne Pratique pour le Traitement des Spondyloarthrites par les Agents Biologiques

  2025cites this paper
• Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study

  2024cites this paper
• Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

  2024cites this paper
• Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review

  2023cites this paper
• Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Remission of psoriatic arthritis 24 h after adalimumab therapy

  2022cites this paper
• Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors

  2022cites this paper
• Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis

  2022cites this paper
• Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage

  2022cites this paper
• Does biologic therapy impact the development of PsA among patients with psoriasis?

  2021cites this paper
• Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors

  2021cites this paper
• Role of diagnostic imaging in psoriatic arthritis: how, when, and why

  2021cites this paper
• COMPARISON OF EFFICACY AND SAFETY OF BASIC ANTI-INFLAMMATORY DRUGS AND GENETICALLY ENGINEERED BIOLOGICAL PRODUCTS IN PSORIATIC ARTHRITIS

  2021cites this paper
• JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials

  2021cites this paper
• Management of particular clinical situations in psoriatic arthritis: an expert’s recommendation document based on systematic literature review and extended Delphi process

  2021cites this paper
• Does current evidence on disease-modifying antirheumatic drugs for psoriatic arthritis reinforce an effect on radiographic progression? Results from a systematic review and meta-analysis

  2021influential citation
• Nail Psoriasis and Psoriatic Arthritis for the Dermatologist

  2020cites this paper
• Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis.

  2020cites this paper
• Efficacy and safety of adalimumab in Japanese patients with psoriatic arthritis and inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs): A prospective, observational study

  2020cites this paper
• Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals

  2019cites this paper
• Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity

  2019cites this paper
• The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review.

  2019cites this paper
• Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases

  2019cites this paper
• Management of psoriatic arthritis

  2019cites this paper
• Clinical Assessment of Spondyloarthritis

  2019cites this paper
• Clinical implications of peripheral new bone formation in psoriatic arthritis: a literature-based review.

  2019cites this paper
• Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study

  2019cites this paper
• Incidence and Predictive Factors for Orthopedic Surgery in Patients with Psoriatic Arthritis

  2018cites this paper
• PORTUGUESE RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS--2015 UPDATE.

  2018cites this paper
• Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis.

  2018cites this paper
• Emerging treatment options for spondyloarthritis.

  2018cites this paper
• Psoriasis and Comorbid Diseases Part II. Implications for Management

  2018cites this paper
• Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis

  2018cites this paper
• Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.

  2017cites this paper
• Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis

  2017cites this paper
• Psoriasis and comorbid diseases: Implications for management.

  2017cites this paper
• Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance

  2017cites this paper
• Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.

  2017cites this paper
• Veterans : Effect of Specialty Care and Geographic Distance Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in

  2017cites this paper
• Psoriasis and comorbid diseases Implications for management

  2017cites this paper
• Identification of Serum miR-146a and miR-155 as Novel Noninvasive Complementary Biomarkers for Ankylosing Spondylitis

  2016cites this paper
• The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

  2016cites this paper
• A Review of Current Evidence for TNF Inhibitor Switching in Psoriatic Arthritis

  2016cites this paper
• Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

  2016cites this paper
• Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis

  2016cites this paper
• Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US

  2016cites this paper
• Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings

  2016cites this paper
• Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study

  2016cites this paper
• Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis

  2016cites this paper
• Etanercept in the Treatment of Psoriatic Arthritis

  2015cites this paper
• EULAR 2015, the Annual European Congress of Rheumatology representing the official annual meeting of the European League Against Rheumatism (EULAR), in Rome, Italy

  2015cites this paper
• Clinical repercussions of introducing biological therapies: the well-controlled patient.

  2015cites this paper
• Therapeutic targets in psoriatic arthritis

  2015cites this paper
• Ustekinumab: The “New Kid on the Block” in the Treatment of Psoriatic Arthritis

  2015cites this paper
• Making the next steps in psoriatic arthritis management: current status and future directions

  2015cites this paper
• IL-17 INHIBITION IN SPONDYLOARTHRITIS: A TARGETED APPROACH IN PSORIATIC ARTHRITIS

  2015cites this paper
• Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA

  2015cites this paper
• Clinical repercussions of introducing biological therapies: the well-controlled patient.

  2015cites this paper
• Pharmacological therapy of spondyloarthritis

  2015cites this paper
• Etanercept in the treatment of psoriatic arthritis.

  2015cites this paper
• Treatment satisfaction of patients with psoriasis.

  2015cites this paper
• IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

  2015cites this paper
• Emerging targets in treating pain

  2015cites this paper
• Developing new evaluation methods in systemic lupus erythematosus

  2015cites this paper
• Spondyloarthritis: a window of opportunity?

  2014cites this paper
• Ustekinumab for the treatment of psoriatic arthritis

  2014cites this paper
• Ustekinumab for the treatment of psoriatic arthritis

  2014cites this paper
• Advances in the management of psoriatic arthritis

  2014cites this paper
• Treatment options for psoriatic arthritis

  2014cites this paper
• Ustekinumab for the treatment of psoriatic arthritis: an update

  2014cites this paper
• Efficacy of tocilizumab in a patient with refractory psoriatic arthritis

  2014cites this paper
• Spondyloarthrite : existe-il une fenêtre d’opportunité ? ☆

  2014cites this paper
• Advances in the management of psoriatic

  2014cites this paper
• Ustekinumab for the treatment of psoriatic

  2014cites this paper
• The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis

  2013cites this paper
• Artritis psoriásica

  year unknowncites this paper